Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$2 Mln
Revenue (TTM)
$0 Mln
Net Profit (TTM)
$0 Mln
ROE
-1.3 %
ROCE
-- %
P/E Ratio
0
P/B Ratio
0.2
Industry P/E
--
EV/EBITDA
-2.3
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
2,013,141
CFO
$-24.36 Mln
EBITDA
$-28.46 Mln
Net Profit
$-32.08 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Painreform (PRFX)
| -34.6 | -29.3 | -34.6 | -81.3 | -86.4 | -79.4 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
|---|---|---|---|---|
|
Painreform (PRFX)
| -80.9 | -33.4 | -68.9 | -70.2 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Painreform (PRFX)
|
2.1 | 1.9 | 0.0 | -4.8 | -- | -93.3 | 0 | 0.2 |
| 8.5 | 466.6 | 195.3 | 21.9 | 12.7 | 8.3 | 23.1 | 1.8 | |
| 16.8 | 198.6 | 17.0 | -23.9 | -96.8 | -63.9 | -- | 4.5 | |
| 4.4 | 80.3 | 0.0 | -34.2 | -- | -366.3 | -- | 7.2 | |
| 3.6 | 2.0 | 1.3 | -6.3 | -- | -79.7 | 0 | 0.5 |
PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based... solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operations. The company was formerly known as PainReform Ltd. and change its name to PRF Technologies Ltd. in January 2026. The company was incorporated in 2007 and is based in Tel Aviv-Yafo, Israel. Address: 65 Yigal Alon St., Tel Aviv-Yafo, Israel, 6744316 Read more
Executive Chairman
Dr. Ehud Geller Ph.D.
Executive Chairman
Dr. Ehud Geller Ph.D.
Headquarters
Tel Aviv-Yafo
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Painreform Ltd (PRFX) is $2.10 (NASDAQ) as of 02-Apr-2026 16:00 EDT. Painreform Ltd (PRFX) has given a return of -86.36% in the last 3 years.
The P/E ratio of Painreform Ltd (PRFX) is 0.03 times as on 31-Mar-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Painreform Ltd (PRFX) are Rs 17.95 and Rs 1.80 as of 04-Apr-2026.
Painreform Ltd (PRFX) has a market capitalisation of $ 2 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Painreform Ltd (PRFX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$-0.01
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.